ADMA Biologics Inc. (ADMA)’s Financial Results Comparing With Immunic Inc. (NASDAQ:IMUX)

Both ADMA Biologics Inc. (NASDAQ:ADMA) and Immunic Inc. (NASDAQ:IMUX) are each other’s competitor in the Biotechnology industry. Thus the contrast of their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ADMA Biologics Inc. 4 17.04 N/A -1.34 0.00
Immunic Inc. 13 0.00 N/A -34.26 0.00

In table 1 we can see ADMA Biologics Inc. and Immunic Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
ADMA Biologics Inc. 0.00% -205.4% -62.4%
Immunic Inc. 0.00% -235.3% -182.3%

Volatility & Risk

ADMA Biologics Inc.’s current beta is 2.7 and it happens to be 170.00% more volatile than Standard & Poor’s 500. From a competition point of view, Immunic Inc. has a 3.72 beta which is 272.00% more volatile compared to Standard & Poor’s 500.


The Current Ratio and Quick Ratio of ADMA Biologics Inc. are 4.6 and 2.4 respectively. Its competitor Immunic Inc.’s Current Ratio is 7 and its Quick Ratio is 7. Immunic Inc. can pay off short and long-term obligations better than ADMA Biologics Inc.

Analyst Ratings

The Recommendations and Ratings for ADMA Biologics Inc. and Immunic Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ADMA Biologics Inc. 0 0 2 3.00
Immunic Inc. 0 0 1 3.00

The upside potential is 125.56% for ADMA Biologics Inc. with average price target of $12. Competitively the average price target of Immunic Inc. is $40, which is potential 185.51% upside. Based on the data given earlier, Immunic Inc. is looking more favorable than ADMA Biologics Inc., analysts belief.

Institutional and Insider Ownership

ADMA Biologics Inc. and Immunic Inc. has shares owned by institutional investors as follows: 50.4% and 1.6%. Insiders owned 7.7% of ADMA Biologics Inc. shares. Competitively, insiders own roughly 0.3% of Immunic Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ADMA Biologics Inc. -2.43% -1.9% -19.2% 14.92% -42.36% 51.46%
Immunic Inc. 1.94% 21.1% 2.94% 71.52% -95.65% 83.31%

For the past year ADMA Biologics Inc. has weaker performance than Immunic Inc.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.